|
Match
|
Document |
Document Title |
|
|
7563783 |
2-methylene-19-nor-(20S-24S)-1α,25-dihydroxyvitamin-D2
Compounds of formula I are provided where X 1 , X 2 , and X 3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions...
|
|
|
7541349 |
2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone
Compounds of formula 1A and 1B are provided where X 1 and X 2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions...
|
|
|
7541348 |
2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalciferol
Compounds of formula I are provided where X 1 and X 2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are...
|
|
|
7538098 |
19-nor-vitamin D analogs with 1,2 or 3,2 heterocyclic ring
19-nor-vitamin D analogs having an additional heterocyclic ring connecting the 3β-oxygen and carbon-2 or the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore,...
|
|
|
7534777 |
Des-C,D analogs of 1α,25-dihydroxy-19-norvitamin D3
Des-C,D 2-methylene-19-norvitamin D 3 analogs are provided including compounds of formula 1, in which R 1 is a straight or branched chain alkyl or alkylene group having from 8 to 27 carbons and...
|
|
|
7531527 |
2-Propylidene-19-nor-vitamin D compounds
2-propylidene-19-nor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by high bone...
|
|
|
7528122 |
Vitamin D analog—NEL, methods and uses thereof
Compounds of formula IA or IB are provided where X 1 , X 2 and X 3 are independently selected from H or hydroxy protecting groups and R 1 is selected from straight or branched chain alkyl groups...
|
|
|
7524980 |
Vitamin D3 lactam derivative
Compounds expressed by the following formula (1) or pharmaceutically permissible solvate thereof which is effective for treating Paget's disease of bone, hypercalcemia or osteoporosis.
In the...
|
|
|
7511030 |
2-methylene-19-nor-(20S-24epi)-1α,25-dihydroxyvitamin D2
Compounds of formula I are provided where X 1 , X 2 , and X 3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions...
|
|
|
7491712 |
Process for preparation of paricalcitol and intermediates thereof
The invention relates to a novel process for the preparation of Paricalcitol and intermediates thereof.
|
|
|
7491711 |
Methods of treatment using 3-desoxy vitamin D3 analogs
The present invention provides a method for treating osteoporosis, hyperparathyroidism or an autoimmune disease in a patient by administering to the patient a 3-desoxy vitamin D 3 analog of the...
|
|
|
7402688 |
2,2-Di-substituted 1alpha,25-dihydroxy-19-norvitamin D derivative
A novel 2,2-di-substituted 19-norvitamin D derivative. It is a compound represented by the general formula (I) wherein R1 and R2 are the same or different and each represents hydroxy and A...
|
|
|
7332482 |
Method for treating benign prostatic hyperplasia
The use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-
cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicament for the...
|
|
|
7323580 |
Crystals of a vitamin D derivative and a method for the preparation thereof
A compound represented by formula (III):
|
|
|
7253293 |
Enzymatic method to produce 7-dehydropregnenolone, vitamin D3-like compounds and derivatives thereof
Provided herein are enzymatic methods of producing steroid compounds such as 7-dehydropregnenolone, hydroxy derivatives thereof and vitamin D2- and D3-like compounds and derivatives thereof. Also...
|
|
|
7244719 |
2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses
This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D 3 and pharmaceutical uses therefor. This...
|
|
|
7241909 |
19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds
Compounds of formula 1 are provided where X 1 , X 2 , and X 3 are independently selected from H or hydroxy protecting groups, and R 1 and R 2 have the definitions provided herein. Such compounds...
|
|
|
7241752 |
17,20(E)-dehydro vitamin D analogs and their uses
This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vit
amin D 3 and pharmaceutical uses therefor. This compound...
|
|
|
7241751 |
2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and its uses
This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound...
|
|
|
7241750 |
2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses
This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound...
|
|
|
7241749 |
2α-Methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses
This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D 3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in...
|
|
|
7238681 |
2-Methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol and its uses
This invention discloses 2-methylene-18,19-dinor-vitamin D analogs, and specifically 2-methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol and pharmaceutical uses therefor. This compound...
|
|
|
7235680 |
2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone
Compounds of formula 1A and 1B are provided where X 1 and X 2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions...
|
|
|
RE39706 |
Crystalline form of a vitamin D analogue
The present invention relates to calcipotriol hydrate—a new crystalline form of calcipotriol—with superior technical properties and with superior stability.
|
|
|
7232810 |
2-methylene-19-nor-vitamin D2 compounds
2-Methylene-19-nor-24(S) and 24(R) derivatives of 1α,25-dihydroxyvitamin D 2 are disclosed. These compounds are characterized by minimal bone calcium mobilization activity and relatively high...
|
|
|
7214671 |
Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3 . This compound is characterized by high bone calcium mobilization activity demonstrating...
|
|
|
7214670 |
Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3 . Administration of this compound increases the life expectancy of human beings, especially...
|
|
|
7211680 |
Vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments
Compounds of Formula I,
wherein Y 1 , Y 2 , R 1 –R 6 , Q and Z are as defined herein, are vitamin D derivatives. These compounds are useful for, e.g., the treatment hyperprolifierative...
|
|
|
7208484 |
Method of synthesizing 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol
A method of making 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol. The method includes the steps of condensing a bicyclic ketone with an allylic phosphine oxide to produce a protected...
|
|
|
7205420 |
Epimerization of analogs of vitamin D
Provided is a method of general applicability of epimerizing a vitamin-D analog having an asymmetric allylic carbon atom at the C-24 position. The method is of particular utility in making...
|
|
|
7205286 |
(20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
This invention discloses (20S)-1α-hydroxy-2α-methyl-19-nor-vitamin D 3 and (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D 3 and pharmaceutical uses therefor. These compounds exhibit pronounced...
|
|
|
7166585 |
24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3
The present invention provides novel C24-sulfone analogs of 1α,25-dihydroxy vitamin D 3 , compositions comprising these compounds and methods of using these compounds as selective inhibitors of...
|
|
|
7115758 |
Vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents
The invention relates to vitamin D derivatives of general formula I,
process for their production, intermediate products of the process as well as the use for the production of pharmaceutical...
|
|
|
7112579 |
26,27-Homologated-20-EPI-2-alkyl-19-nor-vitamin D compounds
This invention provides a novel class of vitamin D related compounds, namely, the 2-alkyl-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have...
|
|
|
7101865 |
24-sulfoximine vitamin D3 compounds
The present invention provides novel sulfoximine compounds, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compounds of the...
|
|
|
7094916 |
(20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
This invention discloses (20S)-1α-hydroxy-2α-methyl-19-nor-vitamin D 3 and (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D 3 and pharmaceutical uses therefor. These compounds exhibit pronounced...
|
|
|
7094776 |
Method of locking 1α-OH of vitamin D compounds in axial orientation
A method of modifying or altering the structure of a 1α-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a...
|
|
|
7094775 |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the breast, e.g., breast cancer, which includes...
|
|
|
7094774 |
26,27-homologated-20-epi-2-alkylidene-19-nor-vitamin D compounds
This invention provides a novel class of vitamin D related compounds, namely, the 2-alkylidene-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds...
|
|
|
7074777 |
Vitamin D derivatives
The object of the present invention is to provide a vitamin D derivative exhibiting excellent physiological activity as medicines, in particular as therapeutic agents for skin disease including...
|
|
|
7071344 |
Vitamin D derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments
The invention relates to novel vitamin D derivatives of general formula (I), a method for the production thereof, intermediate products of the method and the utilization of vitamin D derivatives...
|
|
|
7071179 |
Method of locking 1α-OH of vitamin D compounds in axial orientation
A method of modifying or altering the structure of a 1α-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a...
|
|
|
7056904 |
Method of locking 1α-OH of vitamin D compounds in axial orientation
A method of modifying or altering the structure of a 1α-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a...
|
|
|
7053075 |
Methods for reducing body fat using vitamin D compounds
A treatment for obesity and overweight comprises administering a vitamin D analog. The analog effectively inhibits an increase in body fat to animals at risk and decreases the basal fat content of...
|
|
|
6989377 |
Treating vitamin D responsive diseases
The present invention relates to therapeutics for the prevention and treatment of vitamin D responsive diseases in humans, as well as other animals, through the use of biologically active vitamin D...
|
|
|
6982258 |
Low-calcemic oxime analogs of 1α,25-dihydroxy vitamin D3
The present invention provides novel 16-ene-C25-oxime and 16-ene-C-25-oxime ether analogs of 1α,25-dihydroxy vitamin D 3 , compositions comprising these compounds and methods of using these...
|
|
|
6982257 |
Vitamin D3 derivative and its production method
Provided are 1,25-dihydroxy-2-methylvitamin D3 derivatives expressed by the general formula (I),
[wherein each of R 1 and R 2 is independently a hydrogen atom or a tri(C 1 to C 7 ...
|
|
|
6903083 |
Stabilized hydroxyvitamin D
The invention provides a stabilized 1α-hydroxyvitamin D (“SHVD”) which is particularly well suited for pharmaceutical formulations.
|
|
|
6900191 |
1α-Hydroxyvitamin D5, its synthesis and use in cancer prevention
A compound of formula I:
wherein R1 is hydrogen, R2 is —CH 3 , R3 is —CH 3 , and R4 is hydrogen, useful in cancer prevention and therapy.
|
|
|
6894037 |
2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
This invention provides a novel vitamin D analog, namely, 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol. The compound has the formula:
This 2-substituted compound is characterized...
|